Jiangsu Vcare Held “Firefighting and First Aid” Training

Vcare Enters into Exclusive Partnership with Huadong Medicine to Commercialize its second-generation JAK1 inhibitor, VC005 tablets, in China

August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.

View Details

Jiangsu Vcare Completes Full Patient Enrollment for Phase II Clinical Trial of VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.

View Details

Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare's New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.

View Details

Jiangsu Vcare's Next-Generation TRK Inhibitor Eratrectinib (VC004) Capsules, Have Been Included in Priority Review

Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.

View Details

Jiangsu Vcare Completes Enrollment in Phase III Clinical Trial of Antiplatelet Drug Vicagrel in China

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.

View Details

New Indication Added! Jiangsu Vcare’s Second-Generation Highly Selective JAK1 Inhibitor VC005 Tablets Approved for IND in Oral Treatment of Vitiligo

On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).

View Details